PsiQuantum Raises $1 Billion to Build Million-Qubit Scale, Fault-Tolerant Quantum Computers
PsiQuantum today announced it has raised $1 billion in funding for its Series E round to build the world’s first commercially useful, fault-tolerant quantum computers. This funding will equip the company to break ground on utility-scale quantum computing sites in Brisbane and Chicago, deploy large-scale prototype systems to validate systems architecture and integration, and further advance the performance of its quantum photonic chips and fault-tolerant architecture.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250910135739/en/
Omega, PsiQuantum’s silicon photonic quantum chipset, designed by PsiQuantum and manufactured at GlobalFoundries’ Fab 8 in New York.
Led by funds and accounts managed by affiliates of BlackRock, along with Temasek and Baillie Gifford, this fundraising values the company at $7 billion and brings in new investors, including entities administered by Macquarie Capital, Ribbit Capital, NVentures (NVIDIA’s venture capital arm), Adage Capital Management, Qatar Investment Authority (QIA), Type One Ventures, Counterpoint Global (Morgan Stanley), 1789 Capital, and S Ventures (SentinelOne). The round also included participation from existing investors including Blackbird, Third Point Ventures, and T. Rowe Price Associates, Inc.
PsiQuantum was founded on the premise that commercially valuable quantum computing requires error correction—and therefore on the order of a million physical qubits. Teams worldwide are now racing to build fault-tolerant systems at this scale, and are increasingly facing scaling challenges of manufacturability, cooling, and networking. PsiQuantum’s thesis is that the unique strengths of photonic qubits, combined with direct leverage of high-volume semiconductor manufacturing, provide a fast path through these barriers.
“Only building the real thing—million-qubit scale, fault-tolerant machines—will unlock the promise of quantum computing,” said Prof. Jeremy O’Brien, PsiQuantum co-founder and Chief Executive Officer. “We defined what it takes from day one: this is a grand engineering challenge, not a science experiment. We tackled the hardest problems first—at the architectural and chip level—and are now mass-manufacturing best-in-class quantum photonic chips at a leading U.S. semiconductor fab. With this funding, we’re ready to take the next decisive steps to deliver the full potential of quantum computing.”
“Nearly nine years after we started, we have pushed the technology to an unprecedented level of maturity and performance," said Dr. Pete Shadbolt, PsiQuantum co-founder and Chief Scientific Officer. "We have the chips, we have the switches, we have a scalable cooling technology, we can do networking, we have found the sites, we have the commercial motive and the government support – we’re ready to get on and build utility-scale systems.”
In addition to investment support from NVentures, PsiQuantum is collaborating with NVIDIA across a broad range of development areas, including quantum algorithms and software, GPU-QPU integration and PsiQuantum’s silicon photonics platform.
Since the company’s Series D financing in 2021, PsiQuantum has established a high-volume manufacturing process for its integrated photonic chipset, containing the components needed for photonic quantum computing—all of which perform beyond the state-of-the-art. This chipset is designed by PsiQuantum and manufactured at GlobalFoundries’ Fab 8 in New York—a high-volume, commercial semiconductor foundry.
Critically, PsiQuantum has integrated Barium Titanate (BTO) into its manufacturing flow. BTO is one of the world’s highest-performing electro-optic materials, which makes it ideally suited for ultra-high-performance optical switches; the missing component for scaling optical quantum computing. PsiQuantum manufactures 300mm wafers of BTO at its facilities in California, which are then integrated together with wafers manufactured at GlobalFoundries.
This new funding will enable PsiQuantum to further scale up BTO production towards the volumes needed for utility-scale quantum computing. The BTO-enabled optical switch also has potential in next-generation AI supercomputers, an area of increased interest given rapidly-growing AI workloads—where low-power, high-speed optical networking is increasingly relevant.
In addition to the photonic chips which generate, manipulate and measure qubits, PsiQuantum also develops the cooling, networking, and control systems for utility-scale machines. Due to its photonic approach, the company does not depend on the “chandelier”-style cryostats frequently used in quantum computing and has designed and commissioned a new high-density cooling solution, similar to the modular racks found in a datacenter, with the capacity to cool hundreds of quantum chips in a single cabinet. The company has also demonstrated high-fidelity quantum networking between distant cabinets using standard telecom fiber—a key requirement for most approaches to utility-scale quantum computing.
Tony Kim, Head of the Fundamental Equities Technology Group at BlackRock:
"AI is built on classical computing, which has underpinned the last fifty years of technology. Now, we are at the dawn of an adjacent computing platform – rooted in quantum mechanics – that will allow us to simulate the physical world with transformative accuracy."
Luke Ward, private companies investment manager, Baillie Gifford:
"We first backed PsiQuantum over six years ago, recognising its unique approach to scaling quantum computing. Since then, the company has consistently hit technical milestones while forging deep partnerships across industry and government. With a vision rooted in practicality, PsiQuantum is now positioned at the forefront of what could be a trillion-dollar industry, able to solve some of humanity’s biggest challenges. This goes beyond what is possible with AI.”
About PsiQuantum
PsiQuantum was founded in 2016 and is headquartered in Palo Alto, California. The company’s mission is to build and deploy the world’s first useful quantum computers. PsiQuantum’s photonic approach enables it to leverage high-volume semiconductor manufacturing, existing cryogenic infrastructure, and architectural flexibility to rapidly scale its systems. Learn more at www.psiquantum.com.
View source version on businesswire.com: https://www.businesswire.com/news/home/20250910135739/en/
Contacts
media@psiquantum.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
www.businesswire.com

Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Andersen Consulting Expands Capabilities in Asia Pacific with VDB Loi10.9.2025 16:30:00 EEST | Press release
Andersen Consulting broadens its capabilities in Cambodia, Vietnam, and Laos as VDB Loi brings consulting capabilities to its existing tax and legal offering. Led by Managing Director Jean Loi, who also serves as managing director for Andersen in Cambodia and Vietnam, VDB Loi was founded in 2012 as a tax and legal firm and has been a collaborating firm of Andersen Global since 2021. With the addition of its full suite of consulting services, VDB Loi is now a member of Andersen Consulting offering comprehensive solutions in business strategy, AI, technology transformation, and cybersecurity to complement its existing tax and legal platform. “We have been a part of the Andersen family for several years now and recognize the value and synergy this multidisciplinary approach provides for our clients,” Jean said. “In our current business landscape, it is not enough to be solely a tax firm or solely a legal firm as a single service offering does not effectively cover clients’ overall busines
INNORNA Completes Phase II Enrollment and Vaccination of Bivalent RSV mRNA Vaccine IN00610.9.2025 16:21:00 EEST | Press release
Innorna today announced the completion of enrollment and vaccination in its Phase II clinical trial for IN006, the world’s first bivalent respiratory syncytial virus (RSV) mRNA vaccine currently in development by the company. IN006 is also China's first domestically developed RSV vaccine to enter clinical trials, following IND approval in June 2024. The Phase I trial began with the first subject vaccinated in November 2024. Completion of enrollment and dosing in Phase II marks a milestone toward dose optimization and sets the stage for Phase III efficacy studies. The Phase II study is a randomized, double-blind, placebo-controlled trial conducted in China among healthy adults aged 60 and above. Key study objectives include dose optimization, broader population validation, and booster evaluation for annual revaccination. “This Phase II clinical trial marks a critical step in validating IN006’s scientific hypothesis—delivering broad-spectrum, durable protection against RSV,” said Dr. Lin
Xsolla Web Shop and Singular Join Forces to Deliver Cross-Platform LTV and ROAS Measurement Solutions10.9.2025 16:00:00 EEST | Press release
Xsolla, a global video game commerce company that helps developers launch, grow, and monetize their games, today announced a new mobile-focused Server-to-Server (S2S) integration with Singular, a leading marketing analytics and attribution platform. The integration unifies mobile marketing data with direct-to-consumer web purchases, enabling developers to measure campaign performance and player value more accurately than ever before. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250910813948/en/ Graphic: Xsolla As mobile game makers increasingly turn to Web Shops to expand revenue streams beyond app stores, one challenge has persisted: how to tie those off-platform transactions back to mobile marketing spend. The Xsolla Web Shop + Singular S2S integration closes this gap by treating Web Shop purchases as attributable events, giving developers true Return on Advertising Spend (ROAS) and comprehensive Lifetime Value (LTV) ins
Veritas Capital Closes Ninth Flagship Fund at Hard Cap of $14.4 Billion10.9.2025 16:00:00 EEST | Press release
Veritas Capital (“Veritas”), a leading investor at the intersection of technology and government, today announced the final close of The Veritas Capital Fund IX (“Fund IX”) with $14.4 billion in aggregate capital commitments. Fund IX was significantly oversubscribed, with demand exceeding the hard cap and surpassing the initial target of $13 billion. The fundraise represents a 35% increase over Fund VIII which closed at $10.7 billion in 2022. With the close of Fund IX, Veritas now manages more than $54 billion in assets across its strategies, strengthening its position as a leading investor focused on technology. “Fund IX represents an important step forward for Veritas, and I’m deeply proud of our team and the enduring partnerships that made this milestone possible,” said Ramzi Musallam, Chief Executive Officer and Managing Partner of Veritas. “In one of the most challenging fundraising environments in recent memory, strong demand for Fund IX is a clear endorsement of our strategy and
INTRESO's New Fumigation Treatment Approved in U.S. as a High-Efficacy Alternative to the Damaging Methyl Bromide10.9.2025 16:00:00 EEST | Press release
International Treatment Solutions (INTRESO) Group is pleased to announce the registration of eFUME® by the U.S. Environmental Protection Agency (EPA). The registration marks an important milestone for the U.S. agricultural sector in safeguarding its supply chains and biosecurity. eFUME® is a fast-acting, safe, and effective solution for protecting post-harvest produce, packaged and stored foods, and processing equipment. Suited to a wide variety of fruits, vegetables, grains, and cut flowers, its active ingredient, ethyl formate, is a naturally occurring substance. It is regarded as safe for human health by the U.S. Food and Drug Administration (FDA), yet rapidly and effectively eliminates insect pests, typically within one to 24 hours, resulting in no withholding period and faster shipping. Designed for broad applications, eFUME® is effective against stored product insects, fresh produce pests, mites, quarantine pests of concern, and household insects. It is already registered and wid
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom